reference/2498522

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/2498522

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, Non-U.S. Gov't\|Review
endingPage	1139
issn	1938-3673 0741-5400
issueIdentifier	6
pageRange	1123-1139
publicationName	Journal of Leukocyte Biology
startingPage	1123
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_69f412f6fcf1bf0cfd3997c0e29fdc89 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_30f0d189af63be600107f164e61a2630 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_1a1dc1b99017521061b54762bd5ecbbc http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_332e414602a4f905c4c7f577007d1bb1 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_aa7e4b8419e1a744e1071a4b83e500ad http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_ec6a02b8e992899dadae9c472676f56c http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_4ecf8f8525150e717e69db96af88bd97
bibliographicCitation	Norell H, Moretta A, Silva-Santos B, Moretta L. At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias. J Leukoc Biol. 2013 Dec;94(6):1123–39. doi: 10.1189/jlb.0613312. PMID: 24108703.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6a29093e0ec8fd288b519269eca84665 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_92e353a7898fcf5ba964d510d47e5e91 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e95230cbc05b57bc5517bdf428d4f9b6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-4141-9302 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_566bf97fb40212c975abba442ac08f1e
date	2013-10-09^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1189/jlb.0613312 https://pubmed.ncbi.nlm.nih.gov/24108703
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/4912 https://portal.issn.org/resource/ISSN/1938-3673 https://portal.issn.org/resource/ISSN/0741-5400
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias
discusses	http://id.nlm.nih.gov/mesh/M0023721 http://id.nlm.nih.gov/mesh/M0025425
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D016692Q000276 http://id.nlm.nih.gov/mesh/D007938Q000276 http://id.nlm.nih.gov/mesh/D020544Q000276 http://id.nlm.nih.gov/mesh/D007694Q000276 http://id.nlm.nih.gov/mesh/D018380 http://id.nlm.nih.gov/mesh/D013601Q000276
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D013601Q000473 http://id.nlm.nih.gov/mesh/D007694Q000473 http://id.nlm.nih.gov/mesh/D007938Q000628 http://id.nlm.nih.gov/mesh/D007938Q000473 http://id.nlm.nih.gov/mesh/D015395 http://id.nlm.nih.gov/mesh/D064591 http://id.nlm.nih.gov/mesh/D000818 http://id.nlm.nih.gov/mesh/D006801
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8300 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7874 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10364 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7317 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8167

Showing number of triples: 1 to 53 of 53.